We are live on
!
Find out more
OPPM
Opus Point Partners Management Portfolio holdings
AUM
$55.3M
Turnover
18.46%
1-Year Est. Return
7.48%
This Fund
S&P 500
This Quarter
Est. Return
-1.52%
1 Year Est. Return
-7.48%
3 Year Est. Return
+85.18%
5 Year Est. Return
+168.21%
10 Year Est. Return
–
AUM
$67.6M
AUM Growth
-$6.2M
(-8.4%)
Cap. Flow
-$3.41M
Cap. Flow
% of AUM
-5.05%
Top 10 Holdings %
Top 10 Hldgs %
57.93%
Holding
76
New
1
Increased
16
Reduced
1
Closed
13
Avg Time Held Equity + Options
1.7
years
Top 10 Avg Time Held Equity + Options
0.7
years
Top 20 Avg Time Held Equity + Options
1.2
years
Avg Time Held Equity only
1.8
years
Top 10 Avg Time Held Equity only
0.8
years
Top 20 Avg Time Held Equity only
1.3
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Biogen
BIIB
|
+$259K |
| 2 |
Sarepta Therapeutics
SRPT
|
+$255K |
| 3 |
Exact Sciences
EXAS
|
+$246K |
| 4 |
Nektar Therapeutics
NKTR
|
+$73.7K |
| 5 |
Ligand Pharmaceuticals
LGND
|
+$43.2K |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Regenxbio
RGNX
|
+$506K |
| 2 |
Cellectis
CLLS
|
+$409K |
| 3 |
Supernus Pharmaceuticals
SUPN
|
+$408K |
| 4 |
RUBY
Rubius Therapeutics, Inc
RUBY
|
+$391K |
| 5 |
Wave Life Sciences
WVE
|
+$377K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 58.79% |
| 2 | Miscellaneous | 41.21% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
51
Acadia Pharmaceuticals
ACAD
$3.4B
| $320K | 0.47% |
11,981
| – | – |
2017 Q3
7 quarters
|
|
52
IQVIA
IQV
$44.6B
| $319K | 0.47% |
1,985
| – | – |
2016 Q2
12 quarters
|
|
53
Charles River Laboratories
CRL
$14.6B
| $300K | 0.44% |
2,112
| – | – |
2016 Q4
10 quarters
|
|
54
Grifois
GRFS
$5.13B
| $278K | 0.41% |
13,196
+114
| +0.9% | +$2.17K |
2016 Q2
12 quarters
|
|
55
Gilead Sciences
GILD
$195B
| $276K | 0.41% |
4,082
+415
| +11% | +$27.3K |
2016 Q4
10 quarters
|
|
|
56
Biogen
BIIB
$34.8B
| $263K | 0.39% |
+1,123
| New | +$259K |
2019 Q2
0 quarters
|
|
57
Amgen
AMGN
$235B
| $257K | 0.38% |
1,397
+155
| +12% | +$27.8K |
2014 Q4
18 quarters
|
|
58
Neurocrine Biosciences
NBIX
$13.9B
| $254K | 0.38% |
3,012
+205
| +7% | +$16.8K |
2016 Q3
11 quarters
|
|
59
Exelixis
EXEL
$15.6B
| $244K | 0.36% |
11,440
| – | – |
2018 Q2
4 quarters
|
|
|
60
Ligand Pharmaceuticals
LGND
$5.95B
| $241K | 0.36% |
3,384
+587
| +21% | +$43.2K |
2019 Q1
1 quarter
|
|
61
Agios Pharmaceuticals
AGIO
$1.93B
| $240K | 0.36% |
4,806
| – | – |
2015 Q3
15 quarters
|
|
62
Kyntra Bio
KYNB
$21.7M
| $221K | 0.33% |
195
+2
| +1% | +$2.19K |
2017 Q4
6 quarters
|
|
|
SCTL
63
DELISTED
Societal CDMO, Inc. Common Stock
SCTL
| $115K | 0.17% |
12,659
| – | – |
2016 Q4
10 quarters
|
|
64
AC Immune
ACIU
$244M
| – | – |
-39,801
| Closed | -$201K | – |
|
65
Alkermes
ALKS
$6.73B
| – | – |
-7,722
| Closed | -$282K | – |
|
|
66
Cellectis
CLLS
$111M
| – | – |
-22,309
| Closed | -$409K | – |
|
67
CytomX Therapeutics
CTMX
$525M
| – | – |
-25,284
| Closed | -$272K | – |
|
68
Precigen
PGEN
$2.58B
| – | – |
-32,284
| Closed | -$170K | – |
|
|
69
Regenxbio
RGNX
$473M
| – | – |
-8,832
| Closed | -$506K | – |
|
70
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
| – | – |
-33,529
| Closed | -$320K | – |
|
|
71
Supernus Pharmaceuticals
SUPN
$2.3B
| – | – |
-11,648
| Closed | -$408K | – |
|
72
United Therapeutics
UTHR
$23.2B
| – | – |
-2,199
| Closed | -$258K | – |
|
|
73
Wave Life Sciences
WVE
$629M
| – | – |
-9,716
| Closed | -$377K | – |
|
74
Xencor
XNCR
$1.78B
| – | – |
-10,935
| Closed | -$340K | – |
|
|
SURF
75
DELISTED
Surface Oncology, Inc. Common Stock
SURF
| – | – |
-53,063
| Closed | -$253K | – |
|
Similar funds
KIA
PGA
GX
SCG
TCMV
FCM
DP
SAM
Opus Point Partners Management's Q2 2019 Portfolio in Review
As of Q2 2019, Opus Point Partners Management held 76 positions worth $67.6M, down 8.4% from $73.8M the previous quarter. Its ten largest holdings account for 58% of the portfolio.
Opus Point Partners Management withdrew a net $3.41M in Q2 2019, closing 13 positions and reducing 1 holding. Its most notable exit was Regenxbio, an estimated $506K position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 59% of assets, down from 60% a quarter earlier, followed by Miscellaneous.
Against the trend, Opus Point Partners Management opened a new position in Biogen worth $263K.
- Opus Point Partners Management's largest Q2 2019 buy was Biogen: 1,123 shares worth $263K.
- Opus Point Partners Management added most to Sarepta Therapeutics in Q2 2019, an estimated $255K increase.
- Opus Point Partners Management's biggest Q2 2019 reduction was Celgene Corp, cutting an estimated $274K.
- Opus Point Partners Management fully exited Regenxbio in Q2 2019, selling an estimated $506K.
- Opus Point Partners Management's ten largest holdings make up 58% of its $67.6M portfolio in Q2 2019.
- Opus Point Partners Management opened 1 new position and closed 13 in Q2 2019.
- Opus Point Partners Management's portfolio value fell 8.4% quarter-over-quarter to $67.6M.
Based on Opus Point Partners Management's 13F filing for Q2 2019, filed 14 Aug 2019.